Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: A double drug interaction study

Journal of Clinical Pharmacology

Volumn 47, Issue 12, 2007, Pages 1532-1539

  Dilger, Karin ^a   Fux, Richard ^b   Röck, Daniel ^b   Mörike, Klaus ^b   Gleiter, Christoph H ^b  

^a Dr Falk Pharma GmbH   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Budesonide; Cortisol; CYP3A; Metronidazole

Indexed keywords

16ALPHA HYDROXYPREDNISOLONE; 6BETA HYDROXYBUDESONIDE; 6BETA HYDROXYHYDROCORTISONE; BUDESONIDE; CYTOCHROME P450 3A; HYDROCORTISONE; IMIDAZOLE; KETOCONAZOLE; METRONIDAZOLE; UNCLASSIFIED DRUG;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG MEGADOSE; ENTERITIS; EVENING DOSAGE; HUMAN; HYDROCORTISONE BLOOD LEVEL; MALE; MORNING DOSAGE; NORMAL HUMAN; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; ANTI-BACTERIAL AGENTS; ANTIPROTOZOAL AGENTS; AREA UNDER CURVE; BUDESONIDE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HALF-LIFE; HUMANS; HYDROCORTISONE; MALE; METRONIDAZOLE; TANDEM MASS SPECTROMETRY;

EID: 36148947453     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007308617     Document Type: Article

References (38)

1. Tucker GT, Houston JB, Huang SM Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther. 2001 ; 70: 103-114.
2. Guengerich FP Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol. 1999 ; 39: 1-17.
3. Thummel KE, Wilkinson GR In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol. 1998 ; 38: 389-430.
4. Monahan BP, Ferguson CL, Killeavy ES, Lloyd BK, Troy J., Cantilena LR Jr. Torsades de Pointes occurring in association with terfenadine use. JAMA. 1990 ; 264: 2788-2790.
5. Lal S., Steinhart AH Antibiotic therapy for Crohn's disease: a review. Can J Gastroenterol. 2006 ; 20: 651-655.
6. Dresser GK, Spence JD, Bailey DG Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000 ; 38: 41-57.
7. Maurice M., Pichard L., Daujat M., et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J. 1992 ; 6: 752-758.
8. Wang JS, Backman JT, Kivistö KT, Neuvonen PJ Effects of metronidazole on midazolam metabolism in vitro and in vivo. Eur J Clin Pharmacol. 2000 ; 56: 555-559.
9. Page RL II, Klem PM, Rogers C. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. Ann Pharmacother. 2005 ; 39: 1109-1113.
10. Kounas SP, Letsas KP, Sideris A., Efraimidis M., Kardaras F. QT interval prolongation and Torsades de Pointes due to a coadministration of metronidazole and amiodarone. Pacing Clin Electrophysiol. 2005 ; 28: 472-473.
11. Dilger K., Alberer M., Busch A., et al. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Aliment Pharmacol Ther. 2006 ; 23: 387-396.
12. US Food and Drug Administration. Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. Available at: http://www.fda.gov/cder/guidance/index. htm#clinical%20pharmacology. Accessed August 10, 2007.
13. Papi C., Luchetti R., Gili L., Montanti S., Koch M., Capurso L. Budesonide in the treatment of Crohn's disease: a meta-analysis. Aliment Pharmacol Ther. 2000 ; 14: 1419-1428.
14. Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv Drug Deliv Rev. 2005 ; 57: 303-316.
15. Jönsson G., Åström A., Andersson P. Budesonide is metabolized by cytochrome P450 3A (CYP3A) enzymes in human liver. Drug Metab Dispos. 1995 ; 23: 137-142.
16. Dilger K., Schwab M., Fromm MF Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm Bowel Dis. 2004 ; 10: 578-583.
17. Bar-Meir S., Chowers Y., Lavy A., et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology. 1998 ; 115: 835-840.
18. Armitage EL, Aldhous MC, Anderson N., et al. Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology. 2004 ; 127: 1051-1057.
19. Ged C., Rouillon JM, Pichard L., et al. The increase in urinary excretion of 6 beta-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol. 1989 ; 28: 373-387.
20. Eradiri O., Jamali F., Thomson AB Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. Biopharm Drug Dispos. 1988 ; 9: 219-227.
21. Flockhart DA Drug Interactions-Cytochrome P450 System. Available at: http://medicine.iupui.edu/flockhart/table.htm. Accessed July 3, 2007.
22. Hempfling W., Grunhage F., Dilger K., Reichel C., Beuers U., Sauerbruch T. Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology. 2003 ; 38: 196-202.
23. Sirowej H., Bussemas HH, Harhoff F. Determination of drugs by HPLC with simultaneous UV-detection at two wavelengths. J Clin Chem Clin Biochem. 1985 ; 23: 560.
24. Dilger K., Denk A., Heeg MH, Beuers U. No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology. 2005 ; 41: 595-602.
25. Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol. 2003 ; 59: 713-733.
26. Herzig K., Johnson DW Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy. Nephrol Dial Transplant. 1999 ; 14: 521-523.
27. Cooke CE, Sklar GE, Nappi JM Possible pharmacokinetic interaction with quinidine: ciprofloxacin or metronidazole? Ann Pharmacother. 1996 ; 30: 364-366.
28. Spina E., Pisani F., Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine: an update. Clin Pharmacokinet. 1996 ; 31: 198-214.
29. Vincent F., Glotz D., Kreft-Jais C., Boudjeltia S., Duboust A., Bariety J. Acute kidney failure in a patient treated with cyclosporine A and metronidazole following kidney transplantation. Therapie. 1994 ; 49: 155.
30. Zylber-Katz E., Rubinger D., Berlatzky Y. Cyclosporine interactions with metronidazole and cimetidine. Drug Intell Clin Pharm. 1988 ; 22: 504-505.
31. Obach RS, Walsky RL, Venkatakrishnan K., Houston JB, Tremaine LM In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther. 2005 ; 78: 582-592.
32. Kenworthy KE, Bloomer JC, Clarke SE, Houston JB CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br J Clin Pharmacol. 1999 ; 48: 716-727.
33. Bressler B., Sands BE Review article: Medical therapy for fistulizing Crohn's disease. Aliment Pharmacol Ther. 2006 ; 24: 1283-1293.
34. Perencevich M., Burakoff R. Use of antibiotics in the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2006 ; 12: 651-664.
35. Rutgeerts P., Hiele M., Geboes K., et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995 ; 108: 1617-1621.
36. Sutherland L., Singleton J., Sessions J., et al. Double blind, placebo controlled trial of metronidazole in Crohn's disease. Gut. 1991 ; 32: 1071-1075.
37. Cudmore SL, Delgaty KL, Hayward-McClelland SF, Petrin DP, Garber GE Treatment of infections caused by metronidazole-resistant Trichomonas vaginalis. Clin Microbiol Rev. 2004 ; 17: 783-793.
38. Lamp KC, Freeman CD, Klutman NE, Lacy MK Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet. 1999 ; 36: 353-373.